If you are experiencing significant side effects at your current dose, do not increase
doi: 10.1093/jn/nxy260, Retrieved from Vinelli, V., Biscotti, P., Martini, D., et al
It is not approved for human or animal use and should only be handled by qualified researchers in appropriate laboratory settings
Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics
Studies indicate that GIP can effectively support weight loss, especially when combined with GLP-1 receptor agonists
Two research compounds at maintenance dose is roughly double the per-week cost of either alone, before any volume-discount blend pricing